Background Antiplatelet agents are widely used to prevent cardiovascular events. The risks
and benefits of antiplatelet agents may be different in people with chronic kidney disease …

Background Many patients using haemodialysis for end-stage renal disease (ESRD) require
arteriovenous fistulae (AVF) or grafts. Patency can be variable, and this systematic review …

Patients with end-stage renal disease should have arteriovenous fistula (AVF) formation 3 to
6 months prior to commencing hemodialysis (HD). However, this is not always possible with …

Background Antiplatelet therapy (APT) is often used on anecdotal grounds to improve
vascular access patency. The aim of this study was to assess the role of APT in hemodialysis …

Essentials• Uncertainty remains about antiplatelets for vascular access patency in
hemodialysis patients.• 95 971 people under hemodialysis were followed in a claims …

Background People with end‐stage renal disease (ESRD) often require either the formation
of an arteriovenous fistula (AVF) or an interposition prosthetic arteriovenous graft (AVG) for …

Introduction: Arteriovenous fistulas (AVF) are the preferred choice for vascular access in
hemodialysis. We aim to identify factors that may contribute to AVF failure. Methods: Data …

Clopidogrel irreversibly binds to the P2Y12 platelet receptor and acts as a potent inhibitor of
platelet activation and aggregation. It is currently recommended for the prevention of …

Vascular access failure (VAF) is a critical problem in patients undergoing hemodialysis (HD).
Importantly, VAF impairs the quality of life in patients undergoing HD while imposing high …

Purpose The purpose of this study was to elicit the relationship of antiplatelet therapy (AP) in
maintaining arteriovenous graft (AVG) patency after successful percutaneous …